This will help these facilities provide fast and accurate COVID-19 testing for health care personnel and residents in accordance with recently released guidelines issued by the California Department of Public Health.
The MiraDx lab, which is now exclusively processing COVID-19 tests, has capacity of up to 5,000 tests per day for SNFs to ensure they are able to comply with the state's guidelines, which include: exclusive use of PCR testing with 48-hour turnaround time; baseline testing for all residents and healthcare personnel in facilities that do not currently have a positive case; and testing of 25 % of healthcare personnel every seven days, including staff from multiple shifts and facility locations, with 100 % of each facility's staff being tested each month.
MiraDx's analysis technique can identify as little as four copies of coronavirus RNA in an individual sample, meaning that the virus can be detected at even the early stages of infection and/or in asymptomatic individuals.
Other types of tests currently on the market are either less sensitive (resulting in false negatives) or they do not tell patients when they are no longer contagious, which either leaves them in quarantine too long or presents the risk of them coming out of quarantine too soon.
MiraDx's COVID-19 test has been developed in line with the FDA's Emergency Use Authorization requirements.
Dr. Joanne Weidhaas, MD, PhD, MSM is the co-founder of MiraDx and a professor and vice-chair in the department of radiation oncology at UCLA.
MiraDx is a Los Angeles-based molecular genetics company that identifies, validates, develops, and delivers novel germline biomarker tests for individualized cancer treatments, and now performs COVID-19 testing.
Its goal is to improve human health and advance personalized medicine through the application of novel functional germline biomarkers.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval